These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29501768)

  • 1. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.
    Abotaleb M; Kubatka P; Caprnda M; Varghese E; Zolakova B; Zubor P; Opatrilova R; Kruzliak P; Stefanicka P; Büsselberg D
    Biomed Pharmacother; 2018 May; 101():458-477. PubMed ID: 29501768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for managing metastatic breast cancer.
    Olin JJ; Muss HB
    Oncology (Williston Park); 2000 May; 14(5):629-41; discussion 642-4, 647-8. PubMed ID: 10853456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic breast cancer: understanding current management options.
    McGinn K; Moore J
    Oncol Nurs Forum; 2001 Apr; 28(3):507-12; quiz 513-4. PubMed ID: 11338758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Breast Cancer-Associated Fibroblasts in Tumor Development, Therapy Resistance and Evaluation of Potential Therapeutic Strategies.
    Ruocco MR; Avagliano A; Granato G; Imparato V; Masone S; Masullo M; Nasso R; Montagnani S; Arcucci A
    Curr Med Chem; 2018; 25(29):3414-3434. PubMed ID: 29521203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New agents in development for breast cancer.
    Gao XP; Liu F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Pivot XB; Li RK; Thomas ES; Chung HC; Fein LE; Chan VF; Jassem J; de Mendoza FH; Mukhopadyay P; Roché HH
    Eur J Cancer; 2009 Nov; 45(17):2940-6. PubMed ID: 19683429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endocrine therapy resistance in metastatic breast cancer: mechanisms and clinical implications].
    Orcurto A; Odermatt R; Stravodimou A; Wolfer A
    Rev Med Suisse; 2014 May; 10(431):1102-6. PubMed ID: 24941677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy for metastatic breast cancer.
    Hortobagyi GN
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):56-61. PubMed ID: 3589709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers of multiple drug resistance in breast cancer.
    O'Driscoll L; Clynes M
    Chemotherapy; 2006; 52(3):125-9. PubMed ID: 16612055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent strategies to overcome breast cancer resistance.
    Khan MM; Yalamarty SSK; Rajmalani BA; Filipczak N; Torchilin VP
    Crit Rev Oncol Hematol; 2024 May; 197():104351. PubMed ID: 38615873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.